Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese"

MeSH terms

• Antibodies, Monoclonal*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Bortezomib / therapeutic use
• Dexamethasone / therapeutic use
• Humans
• Lenalidomide / therapeutic use
• Multicenter Studies as Topic
• Multiple Myeloma* / drug therapy
• Neoplasms, Plasma Cell*
• Retrospective Studies